메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 26, Issue 21, 2008, Pages 3652-3653
In reply
Author keywords

[No Author keywords available]
Indexed keywords

IMATINIB; SORAFENIB; STEM CELL FACTOR; SUNITINIB;
EID: 51349140043     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.7444     Document Type: Letter
Times cited : (1)
References (11)
  • 1
    • 43249124980 scopus 로고    scopus 로고
    • Dose selection in phase I studies: Why we should always go for the top
    • Sleijfer S, Wiemer E: Dose selection in phase I studies: Why we should always go for the top. J Clin Oncol 26:1576-1578, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 1576-1578
    • Sleijfer, S.1    Wiemer, E.2
  • 2
    • 20844433223 scopus 로고    scopus 로고
    • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: A randomised trial
    • Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: A randomised trial. Lancet 364:1127-1134, 2004
    • (2004) Lancet , vol.364 , pp. 1127-1134
    • Verweij, J.1    Casali, P.G.2    Zalcberg, J.3
  • 3
    • 39149127634 scopus 로고    scopus 로고
    • Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    • Blanke CD, Rankin C, Demetri G, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 626-632
    • Blanke, C.D.1    Rankin, C.2    Demetri, G.3
  • 4
    • 33746401591 scopus 로고    scopus 로고
    • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    • Debiec-Rychter M, Sciot R, Le Cesne A, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103, 2006
    • (2006) Eur J Cancer , vol.42 , pp. 1093-1103
    • Debiec-Rychter, M.1    Sciot, R.2    Le Cesne, A.3
  • 5
    • 39049100282 scopus 로고    scopus 로고
    • Comparison of two doses of imatinib for the treatment of gastrointestinal stromal tumors (GIST): A meta-analysis based on 1640 patients
    • suppl; abstr 10004, 546s
    • Van Glabbeke MM, Owzar K, Rankin C, et al: Comparison of two doses of imatinib for the treatment of gastrointestinal stromal tumors (GIST): A meta-analysis based on 1640 patients. J Clin Oncol 25:546s, 2007 (suppl; abstr 10004)
    • (2007) J Clin Oncol , vol.25
    • Van Glabbeke, M.M.1    Owzar, K.2    Rankin, C.3
  • 6
    • 34249085905 scopus 로고    scopus 로고
    • Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
    • Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 1753-1759
    • Choi, H.1    Charnsangavej, C.2    Faria, S.C.3
  • 7
    • 23644452642 scopus 로고    scopus 로고
    • Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
    • Zalcberg JR, Verweij J, Casali PG, et al: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751-1757, 2005
    • (2005) Eur J Cancer , vol.41 , pp. 1751-1757
    • Zalcberg, J.R.1    Verweij, J.2    Casali, P.G.3
  • 8
    • 35549008418 scopus 로고    scopus 로고
    • Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/ pharmacodynamic (PKPD) approach
    • suppl; abstr 5027, 241s
    • Houk BE, Bello CL, Michaelson MD, et al: Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/ pharmacodynamic (PKPD) approach. J Clin Oncol 25:241s, 2007 (suppl; abstr 5027)
    • (2007) J Clin Oncol , vol.25
    • Houk, B.E.1    Bello, C.L.2    Michaelson, M.D.3
  • 9
    • 84871467359 scopus 로고    scopus 로고
    • Amato RJ, Harris P, Dalton M, et al: A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol J Clin Oncol 25:241s, 2007 (suppl; abstr 5026)
    • Amato RJ, Harris P, Dalton M, et al: A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol J Clin Oncol 25:241s, 2007 (suppl; abstr 5026)
  • 10
    • 35548931472 scopus 로고    scopus 로고
    • Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results
    • suppl; abstr 5025, 241s
    • Szczylik C, Demkow T, Staehler M, et al: Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol 25:241s, 2007 (suppl; abstr 5025)
    • (2007) J Clin Oncol , vol.25
    • Szczylik, C.1    Demkow, T.2    Staehler, M.3
  • 11
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.